Myelofibrosis Treatment Advances: 2026 Therapies
- Myelofibrosis (MF) management has historically centered on reducing splenomegaly and debilitating constitutional symptoms, with JAK inhibition forming the backbone of therapy.
- This shift is being fueled by a more intentional selection among available JAK-pathway options-particularly for patients with anemia-and a maturing pipeline of add-on and novel-mechanism agents that aim...
- Even as investigational agents generate excitement, the day-to-day reality in MF remains that many patients start with a JAK2 inhibitor to reduce spleen size and symptom burden.
Myelofibrosis (MF) management has historically centered on reducing splenomegaly and debilitating constitutional symptoms, with JAK inhibition forming the backbone of therapy. As the field moves into 2026,the treatment conversation is expanding beyond “how do we control symptoms?” toward “How do we individualize therapy by phenotype and biology-and potentially improve long-term outcomes?”
This shift is being fueled by a more intentional selection among available JAK-pathway options-particularly for patients with anemia-and a maturing pipeline of add-on and novel-mechanism agents that aim to deepen responses,address cytopenias,and,in certain specific cases,test disease-modifying hypotheses.
Reframing First-Line Decisions: Phenotype-Driven Use of Approved Options
Table of Contents
Even as investigational agents generate excitement, the day-to-day reality in MF remains that many patients start with a JAK2 inhibitor to reduce spleen size and symptom burden. what is changing is the precision with which clinicians and pharmacists are approaching that first decision-especially when anemia is a defining problem.
Momelotinib (Ojjaara; GSK) is specifically indicated for patients with either intermediate- or high-risk MF with anemia, because it is increasingly recognized that “anemia” should not be relegated to the fine print but is an important, central determinant of function and treatment response. This is more of an approach by phenotype: patients whose clinical picture is heavily shaped by anemia may prompt earlier consideration of therapies positioned to address both inflammatory symptoms and hemoglobin-related outcomes, rather than cycling through options that primarily target splenomegaly.
In this evolution, for pharmacists, the importance of baseline and longitudinal monitoring (CBC trends, transfusion history, symptom trajectory) and medication-access coordination is accentuated. The “right drug for the right MF phenotype” approach can also reduce downstream treatment disruptions, particularl
Testing Disease Modification: Imetelstat and Survival-Focused Endpoints
The MF pipeline is increasingly willing to test survival-focused endpoints and disease-modifying hypotheses-an important evolution in a field where symptom enhancement has often been the most pragmatic near-term goal.
Geron has highlighted the ongoing growth of imetelstat (Rytelo; Geron) in relapsed/refractory MF through the phase 3 IMpactMF program, including expectations for an interim overall survival analysis in the second half of 2026. While MF remains biologically complex and heterogeneous, a credible signal that therapy can extend survival (not just reduce spleen volume) would meaningfully alter clinical discussions and patient expectations.
Where Pharmacists Fit as MF Care Accelerates
As MF care transforms in 2026,pharmacists are positioned to be the connective tissue between cutting-edge evidence and consistent real-world implementation. that includes aligning therapy choice with phenotype (especially anemia), ensuring molecular testing informs treatment opportunities, managing complex combination regimens, preventing and triaging adverse effects, and helping patients navigate access barriers. The pipeline is pushing MF toward a more personalized, mechanism-driven era-and pharmacists will be essential to making that era practical, safe, and scalable.
REFERENCES
-
OJJAARA (momelotinib) tablets, for oral use.Prescribing facts. U.S. Food and Drug Governance. Accessed via FDA label. chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216873s000lbl.pdf
-
Incyte Announces New Positive Data for INCA033989,its First-In-Class mutCALR-Targeted Monoclonal antibody,in Patients with Myelofibrosis Presented at ASH 2025. Incytecorp. Published December 7, 2025. Accessed January 20, 2026.
Karyopharm Reports Preliminary 2025 Revenue and Anticipates Phase 3 Data in 2026 Karyopharm Therapeutics announced preliminary unaudited revenue of $138.1 million for the full year 2025, a 14% increase compared to $121.1 million in 2024. The company also reaffirmed its expectation of releasing potentially pivotal Phase 3 data throughout 2026.
Revenue Details
the revenue increase reflects continued growth in sales of XPOVIO® (selinexor), Karyopharm’s lead product. XPOVIO is approved for multiple myeloma and diffuse large B-cell lymphoma. The company expects to provide a more detailed financial report during its fourth-quarter and full-year 2025 earnings call.
Upcoming Phase 3 Data
Karyopharm is currently conducting several Phase 3 clinical trials evaluating selinexor in combination with other therapies for various hematologic malignancies. The company anticipates these trials will yield significant data points throughout 2026, potentially leading to expanded indications for XPOVIO. Specifically, the company is focused on trials in multiple myeloma and other B-cell lymphomas.
Official Statement
“We are pleased with our preliminary 2025 revenue, which reflects the continued momentum of XPOVIO,” said Richard G. Kopp,President and Chief Executive Officer of Karyopharm. “We remain focused on executing our clinical development programs and delivering potentially transformative data in 2026.”
Source: Karyopharm therapeutics Investor Relations (January 12, 2026)